Increase in serum creatinine levels after PARP inhibitor treatment

J Obstet Gynaecol. 2023 Dec;43(1):2171781. doi: 10.1080/01443615.2023.2171781.

Authors

Di You^{1

2}, Lan Zhong^{1

2}, Rutie Yin^{1

2}, Liang Song^{1

2}

Affiliations

¹ Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
² Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Chengdu, China.

PMID: 36708521
DOI: 10.1080/01443615.2023.2171781

No abstract available

Keywords: Ovarian cancer; PARP inhibitors; creatinine; gynaecological oncology; olaparib; renal function.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Creatinine
Female
Humans
Ovarian Neoplasms* / drug therapy
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Creatinine
Antineoplastic Agents